NEW YORK (GenomeWeb) – Cancer Genetics said after the close of the market on Monday that its fourth quarter revenues rose 4 percent year over year, falling short of the consensus Wall Street estimate.

For the three months ended Dec. 31, 2017, the firm posted $7.5 million in total revenues, up from $7.2 million a year ago. On average, Wall Street had expected $9.2 million in revenues.